May 30, 2019 – The American Food and Drug Administration (FDA) recently approved Alpelisib (Piqray) to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor …

The PI3K inhibitor Alpelisib (Piqray) for progressing breast cancer in women (and men) Read more »

May 15, 2018 –An increasing number of women who are diagnosed with breast cancer are opting for multigene sequencing instead of the more limited testing for only BRCA1/ BRCA2 mutations, according to a new report. The findings come from the ICanCAre study, published …

Breast cancer: Multigene sequencing replaces BRCA tests Read more »

February 17, 2018 – In a new study, published in JAMA Oncology online on February 15, 2018, a comparison of the performance of 6 prognostic signatures for estrogen receptor (ER) –positive breast cancer was performed in a secondary analysis of a randomized …

Breast Cancer: Performance of prognostic signatures Read more »

January 13, 2018 – The American Food and Drug Administration (FDA) has just approved the first treatment for breast cancer with a certain inherited genetic mutation. At first glance, this announcement may be just one in the series of announcements by the …

Olaparib Tablets (Lynparza): For breast cancer with BRCA gene mutation Read more »

July 27, 2017 – Jewish women of Ashkenazi descent may be at risk for additional genetic mutations that increase their risk of breast cancer, according to a new study just published in JAMA Oncology. Researchers from University of Washington in Seattle …

Ashkenazi Jewish Women: Little-known Gene Mutations May Boost Breast Cancer Risk Read more »

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 …

Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU Read more »

Sacco K, Grech G EPMA J 2015;6(1):15 PMID: 26203310 Abstract Breast cancer is a heterogeneous disease that necessitates proper patient classification to direct surgery, pharmacotherapy, and radiotherapy. Despite patients within the same subgroup receiving similar pharmacotherapy, substantial variation in clinical …

Actionable pharmacogenetic markers for prediction and prognosis in breast cancer Read more »

June 12, 2012 — Two diagnostic tests to identify HER2-positive breast cancer have been approved by the US Food and Drug Administration (FDA) for use as companion diagnostics for the new targeted therapy Pertuzumab [Perjeta]. The tests — HercepTest and …

New Breast Cancer HER2 Diagnostic Tests Approved by FDA Read more »

December 16, 2010  –  Today, the American Food and Drug Administration notified healthcare professionals and patients that it is recommending removing the breast cancer indication for Bevacizumab [Avastin] because the drug has not been shown to be safe and effective …

Bevacizumab [Avastin]: Process for Removal of Breast Cancer Indication Begun Because of Lack of Efficacy Read more »